AUG 28·SEC EDGARLow
MAIER PAUL V sold $3.0M of ETON
MAIER PAUL V sold 50,000 shares of Eton Pharmaceuticals, Inc. (ETON) at an average of $59.07 ($58.64–$61.77, $2.95M total) across 3 trades on 2026-08-28.
StockNASDAQ · US · USDHealthcare · Drug Manufacturers - Specialty & Generic
$ETON
Eton Pharmaceuticals, Inc.
AlphAI earnings readSecond Quarter 2026 · AUG 13Record revenue, with Q2 2026 product sales of $37.6 million, representing 99% growth over Q2 2025; raising 2026 revenue guidance to exceed $145 million.Verdict: strongRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $ETONvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $ETON in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $10.7M 8 txs
BRYNJELSEN SEAN4× · $6.1M
10b5-1 share of filings0%
Top stories · $ETONMore →
AUG 28·finance.yahoo.com
Jim Cramer Explains Mad Money Caller How to Handle Eton Pharmaceuticals (ETON)
Eton Pharmaceuticals (ETON) stock has surged from $30 to over $60, driven by record Q2 sales of $37.6M (up 99% YoY) and adjusted EPS of $0.43. Jim Cramer advised taking partial profits. Management raised 2026 revenue guidance to over $145M but faces risks like gross margin compression and insider selling.
AUG 27·law360.com
Eton's Galzin TM And False Ad Suit Survives Dismissal Bid
Eton Pharmaceuticals can proceed with a lawsuit against Extreme V, alleging trademark infringement and false advertising. The company claims Extreme V marketed a dietary supplement as a treatment for Wilson disease. A Michigan federal judge denied Extreme V's motion to dismiss the case.
ETON sentiment & insider activity
Recent ETON coverage spans earnings, insider activity and regulation.
In the last 30 days, ETON insiders filed 8 SEC Form 4 transactions — no purchases and 8 sales ($10.7M). The most active reporter was BRYNJELSEN SEAN, President & CEO, with 4 filings.
What's driving ETON
The insider sale may signal reduced confidence and could pressure the share price in the short term.
Strong earnings beat and guidance raise suggest upside potential, but insider sales and high valuation may cap near‑term moves.
Potential liability and reputational risk for Eton may pressure its stock.
The insider sale may signal reduced confidence or a liquidity need, potentially pressuring the stock short-term.
Positive earnings surprise and higher guidance may drive short‑term upside.
AlphAI scores every news story that mentions ETON with an AI model for sentiment and relevance, and aggregates insider trades from Eton Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $ETON
Score
MAIER PAUL V sold $3.0M of ETON
MAIER PAUL V sold 50,000 shares of Eton Pharmaceuticals, Inc. (ETON) at an average of $59.07 ($58.64–$61.77, $2.95M total) across 3 trades on 2026-08-28.
1 min read
Jim Cramer Explains Mad Money Caller How to Handle Eton Pharmaceuticals (ETON)
Eton Pharmaceuticals (ETON) stock has surged from $30 to over $60, driven by record Q2 sales of $37.6M (up 99% YoY) and adjusted EPS of $0.43. Jim Cramer advised taking partial profits. Management raised 2026 revenue guidance to over $145M but faces risks like gross margin compression and insider selling.
2 min readEton's Galzin TM And False Ad Suit Survives Dismissal Bid
Eton Pharmaceuticals can proceed with a lawsuit against Extreme V, alleging trademark infringement and false advertising. The company claims Extreme V marketed a dietary supplement as a treatment for Wilson disease. A Michigan federal judge denied Extreme V's motion to dismiss the case.
1 min readKrempa David sold $1.6M of ETON
Krempa David (Chief Business Officer) sold 25,000 shares of Eton Pharmaceuticals, Inc. (ETON) at $65.07 ($1.63M total) on 2026-08-24.
1 min readEton Pharmaceuticals (ETON) Returns To Profit As Valuation Debate Gets Harder To Ignore
Eton Pharmaceuticals (ETON) reported Q2 earnings with a return to profitability and raised full-year 2026 revenue guidance to at least $145M. The stock has seen significant gains, with a 30-day return of 49.03% and a 1-year return of 266.88%. Analysts' consensus price target is $45.67, suggesting a 39% overvaluation, but a DCF model estimates a fair value of $285.41. Risks include pricing pressure and regulatory setbacks.
2 min read
Eton Pharmaceuticals (ETON) Q2 2026 Earnings Call Transcript
Eton Pharmaceuticals (ETON) reported Q2 2026 revenue of $37.6M, up 99% YoY, driven by HEMANGEOL relaunch and pediatric endocrinology growth. FY 2026 revenue guidance raised to over $145M. Adjusted EBITDA was $16.2M (43% margin). ASN-001 licensing and study costs total $7M. Non-GAAP net income was $14.3M ($0.43/diluted share).
2 min readEton Pharmaceuticals CEO Sean Brynjelsen sells $6.08m in stock
Eton Pharmaceuticals (ETON) CEO Sean Brynjelsen sold $6.08m in shares at prices between $60.17 and $62.65 in mid-August. The stock is near its 52-week high, up 262% over the past year. InvestingPro notes the stock may be overvalued. Eton reported strong Q2 2026 earnings, beating estimates with $0.43 EPS and $37.6m revenue, driven by rare-disease portfolio growth.
1 min readBRYNJELSEN SEAN sold $6.1M of ETON
BRYNJELSEN SEAN (President & CEO) sold 100,000 shares of Eton Pharmaceuticals, Inc. (ETON) at an average of $60.88 ($60.17–$62.65, $6.09M total) across 4 trades over 2026-08-19 to 2026-08-20.
1 min readForecast: Analysts Think Eton Pharmaceuticals, Inc.'s (NASDAQ:ETON) Business Prospects Have Improved Drastically
Analysts upgraded Eton Pharmaceuticals' (ETON) 2026 revenue forecast to $150M (up 42% YoY) and EPS to $1.09 (up 145%). The price target increased 30% to $71.00. The stock gained 51% in the last 7 days. Analysts expect growth to accelerate, outpacing industry averages.
2 min read
Dow Jones falls 122.81 points, or 0.23%, to 53,609.60 at open
The Dow Jones Industrial Average fell about 123 points, or 0.23%, to 53,609.60 at the open and closed Friday down about 108 points to 53,732.41, extending a weekly loss to 0.6%. The S&P 500 rose 0.4% to 7,785.76 and the Nasdaq gained 0.1% to 26,729.16. Earnings drove stock moves: Eton Pharmaceuticals (ETON) rose over 44% on results and FY26 guidance, while KinderCare (KLC) fell about 46% after weaker results and lower FY26 guidance. Investors also digested weaker consumer sentiment and retail sa
6 min read